US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

AI Healthcare

619.81

+51.028.97%

Number of Gainers:4

Number of Losers:- -

Number of Flat:- -

PE:- -

High:626.14

Open:571.03

Low:571.03

Close:568.79

Loading ...

Why Shares of Tempus AI Are Jumping Higher This Week

Tempus AI Inc. COO Ryan Fukushima Reports Disposal of Common Shares

Crispr Therapeutics call volume above normal and directionally bullish

Director Jennifer A. Doudna Reports Disposal of Common Shares in Tempus AI Inc

CAVA, TEM, or SMCI: Which Growth Stock Could Deliver the Highest Upside?

Recursion Pharmaceuticals call volume above normal and directionally bullish

BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy

Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?

Analysts Offer Insights on NA Companies: Tempus AI, Inc. Class A (TEM) and Rapport Therapeutics, Inc. (RAPP)

Roadzen’s DrivebuddyAI Awarded Patent for Real-Time Driver Drowsiness Detection — Crosses 1.8 Billion Kilometers of Real-World AI Driving Data

Beam Therapeutics Inc. Receives FDA Orphan Drug Designation for BEAM-101 in Sickle Cell Disease Treatment

Beam Therapeutics Inc - Beam-101 Safety Profile Consistent With Busulfan Conditioning

THOMSON REUTERS

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to Beam-101 for the Treatment of Sickle Cell Disease

THOMSON REUTERS

Tempus AI short report addressed issues mostly known, says TD Cowen

tempus AI Inc Class A call volume above normal and directionally bullish

Tempus AI Stock Jumps 9% After Introducing xM for Treatment Response Monitoring

Tiger Newspress

Tempus AI Inc. Unveils xM Assay to Enhance Monitoring of Immunotherapy Response in Advanced Cancer Patients

Tempus Introduces Xm, an Assay to Monitor Immunotherapy Response for Patients With Advanced Cancers

THOMSON REUTERS

The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip

Tempus AI announces expansion of Tempus One

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4611/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4611","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","market":"US","secType":"PLATE","nameCN":"AI Healthcare","latestPrice":619.81287,"timestamp":1749239999999,"preClose":568.7886,"halted":0,"volume":79672402,"delay":0,"changeRate":0.089707,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":51.024292,"latestTime":"06-06 16:00:00 EDT","open":571.0336,"high":626.13544,"low":571.0336,"amount":1289275382.716072,"amplitude":0.096876,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1749254400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":4.231334,"peRate":-8.665669,"turnoverRate":0.119637,"increases":4,"decrements":0,"flats":0,"marketCap":18454890496,"floatMarketCap":13646941824},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","high":626.13544,"amplitude":0.096876,"preClose":568.7886,"low":571.0336,"pbRate":"4.231334","latestPrice":619.81287,"volume":79672402,"delay":0,"open":571.0336,"prevYearClose":530.4984,"prevWeekClose":532.1039,"prevMonthClose":532.1039,"prevQuarterClose":527.803,"fiveDayClose":532.1039,"twentyDayClose":587.4983,"sixtyDayClose":594.3155,"secType":"PLATE","market":"US","turnoverRate":0.119637,"peRate":-8.665669,"marketCap":18454890496,"floatMarketCap":13646941824,"timestamp":1749239999999,"nameCN":"AI Healthcare"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4611\",,,,undefined,":{"bkCode":"BK4611","up":4,"down":0,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4611\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541862004","title":"Why Shares of Tempus AI Are Jumping Higher This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2541862004","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541862004?lang=en_us&edition=fundamental","pubTime":"2025-06-07 01:55","pubTimestamp":1749232500,"startTime":"0","endTime":"0","summary":"Tempus AI is developing innovative AI solutions for the treatment of cancer and other diseases.Shares of Tempus AI plummeted after short-seller Spruce Point Capital Management released a critical report on the company.TD Cowen is unalarmed by the information contained in Spruce Point's report.While it's certainly an encouraging sign for current shareholders to see that TD Cowen is unmoved in its opinion despite Spruce Point's report, prospective investors may want to keep their distance for the time being. Investors will likely have to wait until August for the second-quarter 2025 financial results, but in the meantime, those eager to buy shares may want to see if there are additional developments before adding a position.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/06/06/why-shares-of-tempus-ai-are-jumping-higher-this-we/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4121","LU1861558580.USD","BK4611","LU1861559042.SGD","BK4613","TEM"],"gpt_icon":1},{"id":"2541678005","title":"Tempus AI Inc. COO Ryan Fukushima Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2541678005","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541678005?lang=en_us&edition=fundamental","pubTime":"2025-06-06 04:16","pubTimestamp":1749154568,"startTime":"0","endTime":"0","summary":"Ryan Fukushima, Chief Operating Officer of Tempus AI Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL7dKnr8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Tempus AI Inc. COO Ryan Fukushima Reports Disposal of Common Shares","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4613","BK4121","LU1861558580.USD","BK4611","LU1861559042.SGD","TEM"],"gpt_icon":1},{"id":"2541070669","title":"Crispr Therapeutics call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2541070669","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541070669?lang=en_us&edition=fundamental","pubTime":"2025-06-06 01:25","pubTimestamp":1749144318,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in Crispr Therapeutics (CRSP) with 6,908 calls trading, 3x expected, and implied vol increasing almost 4 points to 63....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/crispr-therapeutics-call-volume-above-normal-and-directionally-bullish-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/crispr-therapeutics-call-volume-above-normal-and-directionally-bullish-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4611","CRSP","BK4556","LENZ","BK4539","BK4588","BK4139","BK4585","BK4007","LU1861559042.SGD","LU1861558580.USD"],"gpt_icon":0},{"id":"2541096708","title":"Director Jennifer A. Doudna Reports Disposal of Common Shares in Tempus AI Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2541096708","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541096708?lang=en_us&edition=fundamental","pubTime":"2025-06-05 04:16","pubTimestamp":1749068164,"startTime":"0","endTime":"0","summary":"Jennifer A. Doudna, a Director at Tempus AI Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 04, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL8bP6rK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Director Jennifer A. Doudna Reports Disposal of Common Shares in Tempus AI Inc","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4611","LU1861559042.SGD","LU1861558580.USD","BK4613","TEM"],"gpt_icon":1},{"id":"2541895098","title":"CAVA, TEM, or SMCI: Which Growth Stock Could Deliver the Highest Upside?","url":"https://stock-news.laohu8.com/highlight/detail?id=2541895098","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541895098?lang=en_us&edition=fundamental","pubTime":"2025-06-05 00:32","pubTimestamp":1749054724,"startTime":"0","endTime":"0","summary":"While concerns over trade wars have eased, the U.S. stock market continues to be volatile due to persistent macro uncertainty. Despite the ongoing ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/cava-tem-or-smci-which-growth-stock-could-deliver-the-highest-upside?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/cava-tem-or-smci-which-growth-stock-could-deliver-the-highest-upside?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","BK4209","LU1861559042.SGD","SMCI","BK4588","BK4170","BK4543","LU1861220033.SGD","CAVA","BK4613","BK4611","LU1861558580.USD","BK4585","LU1861215975.USD","TEM","LU0053671581.USD"],"gpt_icon":0},{"id":"2540675090","title":"Recursion Pharmaceuticals call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2540675090","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540675090?lang=en_us&edition=fundamental","pubTime":"2025-06-04 23:25","pubTimestamp":1749050710,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 43,953 calls trading, 8x expected, and implied vol increasing almost 16 point...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/recursion-pharmaceuticals-call-volume-above-normal-and-directionally-bullish-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/recursion-pharmaceuticals-call-volume-above-normal-and-directionally-bullish-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4609","RXRX","BK4539","BK4611","BK4139","BK4548"],"gpt_icon":0},{"id":"2541737093","title":"BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2541737093","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541737093?lang=en_us&edition=fundamental","pubTime":"2025-06-04 22:58","pubTimestamp":1749049080,"startTime":"0","endTime":"0","summary":"Beam TherapeuticsBEAM announced that the FDA has granted an orphan drug designation to its investigational genome-editing candidate, BEAM-101, for the treatment of sickle cell disease , an inherited blood disorder.The FDA grants orphan drug designation to support the development of medicines for rare disorders that affect fewer than 200,000 people in the United States. The designation makes the sponsor eligible to receive seven years of market exclusivity following a potential approval, along with the exemption of FDA application fees and tax credits for qualified clinical studies.Shares of Beam Therapeutics were up 4.3% yesterday following the announcement of the news.However, the stock has plunged 32% so far this year compared with the industry’s decline of 2.9%.In December 2024, the company announced new safety and efficacy data from the BEACON study evaluating BEAM-101 in SCD patients with severe vaso-occlusive crises.The data showed that treatment with BEAM-101 led to a robust and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beam-fdas-orphan-drug-status-145800778.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0889565916.HKD","LU2362540622.SGD","NTLA","BK4533","LU0234570918.USD","IE00B2B36J28.USD","LU2236285917.USD","BK4567","IE00BFTCPJ56.SGD","BK4139","LU0320765992.SGD","LU2362541273.HKD","LU1778281490.HKD","LU2462157665.USD","BK4505","LU0417517546.SGD","LU2237438978.USD","LU0061475181.USD","LU0058720904.USD","LU1093756325.SGD","IE0002270589.USD","BK4535","LU2456880835.USD","IE00B19Z3581.USD","IE0009355771.USD","SGXZ57979304.SGD","LU0109394709.USD","BK4585","BK4611","IE00B19Z3B42.SGD","LU1430594728.SGD","SG9999013999.USD","BEAM","CRSP","IE00B894F039.SGD","LU0079474960.USD","IE00B19Z9P08.USD","BK4588","LU1585245621.USD","LU2362541513.USD","LU1861558580.USD","VRTX","LU1035775433.USD","LU2324357040.USD","IE00BJJMRZ35.SGD","LU1093756168.USD","IE00BZ9MQY76.HKD","SCD","SG9999001176.SGD","SG9999001176.USD"],"gpt_icon":0},{"id":"2541093732","title":"Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?","url":"https://stock-news.laohu8.com/highlight/detail?id=2541093732","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541093732?lang=en_us&edition=fundamental","pubTime":"2025-06-04 20:55","pubTimestamp":1749041700,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics is currently evaluating two in vivo candidates, namely CTX310 and CTX320, in separate early-stage studies, targeting ANGPTL3 and lipoprotein [Lp], respectively — both associated with atherosclerotic heart disease.Last month, CRSP reported initial top-line data from the first 10 patients acrossthe first four cohorts of the phase I study on CTX310. A single dose demonstrated dose-dependent decreases in low-density lipoprotein  and triglyceride  levels, with peak reduction of up to 82% in TG and up to 81% in LDL.These results have raised excitement around CTX320, a readout from which is expected later in the second quarter of 2025. CRISPR Therapeutics also intends to advance two additional in vivo programs into the clinic by year-end, further expanding its footprint in this emerging modality.The company is currently lagging behind Intellia TherapeuticsNTLA, which is one of the few companies with multiple clinical-stage in vivo gene editing programs. Intellia is advanci","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crispr-build-casgevys-success-vivo-125500765.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4198","HAE","LU0205194284.USD","LU1169589451.USD","BK4556","CRSP","IE00BLDYK493.USD","BK4153","LDL","IE00B64QTZ34.USD","TG","BK4090","BK4611","NTLA","LU1169590202.USD","BK4585","LU1861559042.SGD","BK4588","BGSX","LU0012050646.USD","LU0205193047.USD","LU1861558580.USD","BK4139","LU0106261612.USD","BEAM","BK4535","BK4505"],"gpt_icon":0},{"id":"2540087637","title":"Analysts Offer Insights on NA Companies: Tempus AI, Inc. Class A (TEM) and Rapport Therapeutics, Inc. (RAPP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2540087637","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540087637?lang=en_us&edition=fundamental","pubTime":"2025-06-03 23:10","pubTimestamp":1748963410,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on Tempus AI, Inc. Class A (TEM – Research Report) and Rapport ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-tempus-ai-inc-class-a-tem-and-rapport-therapeutics-inc-rapp-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-tempus-ai-inc-class-a-tem-and-rapport-therapeutics-inc-rapp-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4613","NA","BK4611","LU1861559042.SGD","BK4141","LU1861558580.USD","RAPP","BK4121","TEM","BK4007"],"gpt_icon":0},{"id":"2540803826","title":"Roadzen’s DrivebuddyAI Awarded Patent for Real-Time Driver Drowsiness Detection — Crosses 1.8 Billion Kilometers of Real-World AI Driving Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2540803826","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540803826?lang=en_us&edition=fundamental","pubTime":"2025-06-03 21:01","pubTimestamp":1748955660,"startTime":"0","endTime":"0","summary":"New Patent Positions DrivebuddyAI to Lead India’s Upcoming Road Safety Mandates, Achieves 72% Accident Reduction Across Fleets. NEW YORK, June 03, 2025  -- Roadzen Inc.  , a global leader in AI at the intersection of insurance and mobility, today announced that its DrivebuddyAI platform has been granted a patent in India for its Real-Time Driver Drowsiness Detection Algorithm.DrivebuddyAI’s patented system leverages AI and computer vision to monitor over 92 real-time eye and facial cues, enabling early detection of driver fatigue and triggering instant alerts—helping prevent accidents before they occur. The newly granted patent strengthens Roadzen’s expanding global IP portfolio, with additional filings underway in the U.S. and Europe.According to the U.S. National Highway Traffic Safety Administration , crashes involving at least one distracted driver accounted for 29% of all motor vehicle crashes and costs. This underscores the urgent need for real-time safety technologies like Drive","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/roadzen-drivebuddyai-awarded-patent-real-130100836.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4556","BK4131","BK4611","CARD","BK4585","BK4505","BK4535","BEAM","RDZNW","ARAI","BK4139"],"gpt_icon":0},{"id":"2540927775","title":"Beam Therapeutics Inc. Receives FDA Orphan Drug Designation for BEAM-101 in Sickle Cell Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2540927775","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540927775?lang=en_us&edition=fundamental","pubTime":"2025-06-03 19:00","pubTimestamp":1748948435,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., June 03, 2025 - Beam Therapeutics Inc.  announced that the U.S. Food and Drug Administration  has granted orphan drug designation to BEAM-101, an investigational genetically modified cell therapy for treating sickle cell disease . This designation underscores the critical need for innovative treatments for SCD, a debilitating disorder affecting approximately 100,000 people in the U.S. BEAM-101, the lead program in Beam's hematology franchise, has shown promise in clinical trials, demonstrating significant increases in fetal hemoglobin and reductions in sickle hemoglobin among patients. The FDA's orphan drug designation offers potential benefits, including tax credits for clinical trials and a possible seven years of market exclusivity post-approval. Beam Therapeutics continues to advance its BEACON Phase 1/2 clinical trial, with plans to dose 30 patients by mid-2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligenc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL4MCqP5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2095319765.USD","LU2210150020.SGD","LU2210149790.SGD","BEAM","IE00BGHQF748.EUR","BK4556","BK4139","BK4585","IE00BKPKM429.USD","BK4505","BK4611","BK4535","NDAQ","IE00B64PRP62.GBP","BK4588","BK4112"],"gpt_icon":0},{"id":"2540775947","title":"Beam Therapeutics Inc - Beam-101 Safety Profile Consistent With Busulfan Conditioning","url":"https://stock-news.laohu8.com/highlight/detail?id=2540775947","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540775947?lang=en_us&edition=fundamental","pubTime":"2025-06-03 19:00","pubTimestamp":1748948401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nTUA3CKJQ9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BEAM","BK4588","BK4556","BK4611","BK4535","BK4585","BK4139","BK4505"],"gpt_icon":0},{"id":"2540577531","title":"Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to Beam-101 for the Treatment of Sickle Cell Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2540577531","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540577531?lang=en_us&edition=fundamental","pubTime":"2025-06-03 19:00","pubTimestamp":1748948401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nTUA3CKJQ9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4556","BK4139","BK4588","BK4585","BEAM","BK4535","BK4505","BK4611"],"gpt_icon":0},{"id":"2540424794","title":"Tempus AI short report addressed issues mostly known, says TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2540424794","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540424794?lang=en_us&edition=fundamental","pubTime":"2025-06-02 23:50","pubTimestamp":1748879407,"startTime":"0","endTime":"0","summary":"TD Cowen says Tempus AI (TEM) shares were down 16% last week presumably in response to a Spruce Point short report. The analyst found many of the i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tempus-ai-short-report-addressed-issues-mostly-known-says-td-cowen-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tempus-ai-short-report-addressed-issues-mostly-known-says-td-cowen-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","LU1861559042.SGD","TD","BK4127","BK4611","BK4207","TEM","COWN","BK4585","BK4613","LU1861558580.USD","BK4566"],"gpt_icon":0},{"id":"2540579151","title":"tempus AI Inc Class A call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2540579151","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540579151?lang=en_us&edition=fundamental","pubTime":"2025-06-02 22:45","pubTimestamp":1748875505,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in tempus AI (TEM) Inc Class A with 38,181 calls trading, 2x expected, and implied vol increasing almost 2 points to 8...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tempus-ai-inc-class-a-call-volume-above-normal-and-directionally-bullish-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tempus-ai-inc-class-a-call-volume-above-normal-and-directionally-bullish-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861558580.USD","LU1861559042.SGD","BK4613","TEM","BK4611","BK4121"],"gpt_icon":0},{"id":"2540798223","title":"Tempus AI Stock Jumps 9% After Introducing xM for Treatment Response Monitoring","url":"https://stock-news.laohu8.com/highlight/detail?id=2540798223","media":"Tiger Newspress","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540798223?lang=en_us&edition=fundamental","pubTime":"2025-06-02 22:20","pubTimestamp":1748874003,"startTime":"0","endTime":"0","summary":"$Tempus AI$ stock rose more than 9% in premarket trading after announcing xM for treatment response monitoring, TRM, a liquid biopsy assay intended to detect molecular response to immune-checkpoint inhibitor therapy in advanced solid tumors.xM for TRM is the newest addition to Tempus’ growing portfolio of sensitive assays for monitoring molecular response and minimal residual disease. It is currently available for research use only, with clinical availability expected later this year.“Our compre","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"715ea2be3c240e157af090fc4d598bc8","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tempus-ai-introduces-xm-for-treatment-response-monitoring-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Tempus AI Stock Jumps After Introducing xM for Treatment Response Monitoring","news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861558580.USD","BK4613","TEM","LU1861559042.SGD","BK4611","BK4121"],"gpt_icon":0},{"id":"2540174798","title":"Tempus AI Inc. Unveils xM Assay to Enhance Monitoring of Immunotherapy Response in Advanced Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2540174798","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540174798?lang=en_us&edition=fundamental","pubTime":"2025-06-02 20:30","pubTimestamp":1748867414,"startTime":"0","endTime":"0","summary":"Tempus AI Inc. has announced the introduction of xM for treatment response monitoring , a liquid biopsy assay designed to detect molecular response to immune-checkpoint inhibitor  therapy in advanced solid tumors. This new assay is part of Tempus' expanding portfolio aimed at monitoring molecular response and minimal residual disease . Currently available for research use only, clinical availability is anticipated later this year. The xM for TRM assay tracks changes in circulating tumor DNA  dynamics over time, enabling early assessment of molecular response in patients undergoing ICI treatments. Tempus is set to present new data on xM for TRM at the 2025 American Society of Clinical Oncology  Annual Meeting, emphasizing the assay's potential to aid clinicians in monitoring treatment response and refining therapeutic strategies for patients with advanced cancers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"715ea2be3c240e157af090fc4d598bc8","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDLbQy3MV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEM","BK4121","BK4613","LU1861558580.USD","LU1861559042.SGD","BK4611"],"gpt_icon":1},{"id":"2540989097","title":"Tempus Introduces Xm, an Assay to Monitor Immunotherapy Response for Patients With Advanced Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2540989097","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540989097?lang=en_us&edition=fundamental","pubTime":"2025-06-02 20:30","pubTimestamp":1748867400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"715ea2be3c240e157af090fc4d598bc8","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nTUA5CSMBR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1861559042.SGD","TEM","BK4611","BK4613","LU1861558580.USD","BK4121"],"gpt_icon":0},{"id":"2540760986","title":"The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=2540760986","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540760986?lang=en_us&edition=fundamental","pubTime":"2025-06-02 19:45","pubTimestamp":1748864700,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics has the potential to generate significant breakthroughs in gene editing.Regeneron's biggest growth driver is still performing well, and it is developing newer medicines.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/06/02/the-2-smartest-beaten-down-biotech-stocks-to-buy-o/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4534","LU0943347566.SGD","LU2756315664.SGD","BK4083","LU0820562030.AUD","LU0820561909.HKD","LU0320765646.SGD","LU0354030438.USD","LU1778281490.HKD","LU1861558580.USD","BK4504","LU1093756325.SGD","BK4581","LU0823411888.USD","LU1069344957.HKD","HD","LU1551013425.SGD","LU1989772840.SGD","LU0079474960.USD","BK4566","SCD","IE00B1XK9C88.USD","CRSP","LU0868494708.USD","LU0823434583.USD","IE00BWXC8680.SGD","BK4585","LU1551013342.USD","LU0823434740.USD","LU1496350502.SGD","BK4611","IE00BZ1G4Q59.USD","BK4588","LU1162221912.USD","LU1674673428.USD","SG9999001440.SGD","BK4567","BK4533","LU0868494617.USD","IE00BSNM7G36.USD","LU0689472784.USD","LU1861559042.SGD","BK4556","LU0354030511.USD","LU1989772923.USD","BK4139","LU1674673691.USD","LU2756315318.SGD","LU1496350171.SGD","LU0234572021.USD"],"gpt_icon":0},{"id":"2540730939","title":"Tempus AI announces expansion of Tempus One","url":"https://stock-news.laohu8.com/highlight/detail?id=2540730939","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540730939?lang=en_us&edition=fundamental","pubTime":"2025-06-02 04:10","pubTimestamp":1748808604,"startTime":"0","endTime":"0","summary":"Tempus AI (TEM) announced the expansion of Tempus One-its generative AI clinical assistant-with direct integration into electronic health record, E...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tempus-ai-announces-expansion-of-tempus-one-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tempus-ai-announces-expansion-of-tempus-one-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861559042.SGD","TEM","BK4611","BK4613","LU1861558580.USD","BK4121"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":56,"code":"91000000","status":"200"}]}}